Biotech Firm Arcturus Therapeutics Faces Mounting Pressure Ahead of Earnings

Shares of Arcturus Therapeutics are experiencing a severe downturn, weighed down by a combination of disappointing quarterly projections and newly disclosed legal challenges. The stock declined an additional 4.05% yesterday, closing at $8.29 and marking its fourth consecutive day of losses.

The company’s troubles intensified with the revelation that two law firms have initiated investigations into Arcturus. The probes focus on potential securities law violations, which were triggered by an October 22nd press release concerning interim Phase 2 trial data for ARCT-032. This inhaled mRNA therapy for cystic fibrosis failed to demonstrate significant improvement in the lung function measure FEV1, causing the stock to plummet more than 50% upon the announcement. These legal developments Read more...